• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA issues revised draft guidances for blood glucose monitors

November 29, 2018 By Sarah Faulkner

FDA-logo-newThe FDA issued two revised draft guidances today relating to over-the-counter and prescription blood glucose monitors.

The new documents, which are intended to update guidances issued in 2016, were based on feedback from stakeholders, who requested more clarification on design considerations and recommended standards, according to the U.S. regulatory agency.

The guidances include recommendations for the medtech industry about the kind of information that should be included premarket submission packages for blood glucose monitoring test systems.

FDA chief Dr. Scott Gottlieb noted that there are important distinctions to be made between point-of-care and over-the-counter blood glucose monitors. People who use over-the-counter glucose meters and strips are extremely diverse in age, vision, training and dexterity – all of which could impact the accurate use of blood glucose monitoring systems.

People in a healthcare setting could have physiological variables that could impact the accuracy of the systems, according to the FDA commissioner.

“For the millions of Americans with diabetes, monitoring blood glucose levels is a part of daily life. It’s critical that patients with diabetes have access to blood glucose monitors that are safe, accurate, and easy to use. That’s why the FDA has been modernizing our recommendations for the design and performance of these devices,” Gottlieb said in prepared remarks.

“We’re committed to improving the safety and performance of medical devices, and to taking new steps to help make sure that products continually incorporate new technology that can improve safety and better meet the needs of patients and providers,” he added. “The updated draft guidances issued today include recommendations to help ensure greater accuracy, reliability, and safe use of blood glucose monitoring test systems for each setting.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS